Provider Systems and Academic Medical Centres - Business Model Strategies for Payers & Governments - Private and Public Funding and Personalized Medicine Reimbursement - Revisions to Current Payment Systems and intellectual property - How to Gain Market Penetration in the EU - Cost-effectiveness and Business Value of Personalized Medicine - Therapeutics and Companion Diagnostics
We are very pleased to partner with Astellas to help maximize the benefits of their innovative new drugs with companion diagnostics
from our development and commercialization engine.
No Longer required as a Companion Diagnostic
Test with Ponatinib
QIAGEN's leadership in companion diagnostics
continues to grow, transforming patient care around the world," said Thierry Bernard, Senior Vice President, Head of the Molecular Diagnostics Business Area and a member of the Executive Committee of QIAGEN.
QIAGEN today announced a collaboration agreement with AstraZeneca PLC for the co-development and commercialization of a liquid biopsy-based companion diagnostic
to be paired with IRESSA, AstraZeneca s targeted therapy for non-small cell lung cancer (NSCLC).
As pharmaceutical companies prepare for the wave of expiring blockbuster patents, they're looking at companion diagnostics
to help identify patients for targeted therapies," said David Richardson, research manager at Cutting Edge Information.
com/research/wt6gdh/personalized) has announced the addition of the "Personalized Medicine, Targeted Therapeutics and Companion Diagnostic
Market to 2019 - Strategic Analysis of Industry Trends, Technologies, Participants, and Environment" report to their offering.
Individualized or personalized medicine aims to increase the efficacy of therapeutics via genetic testing and companion diagnostics
Personalized Medicine Therapeutics and Associated Companion Diagnostics
(CDx) are tests designed to confirm the presence of a specific biomarker to assist physicians in selecting effective therapies for their patients, based on the individual characteristics of each person.
This data-driven characterization of the Companion Diagnostics
and Personalized Medicine field is a hands-on document that can be used for competitive benchmarking, business planning, and strategy developmentall the data that have been collected in this industry analysis are presented and they form the basis for the conclusions drawn throughout the market report presented in a format enabling drag-and-drop into business presentations/business plansthis Market Report is written and delivered to customers in PowerPoint format.
This agreement is not only an acknowledgement of our companion diagnostic
technology platforms, but also an important strategic step in expanding our companion diagnostics
partnerships with leading pharmaceutical companies," said Dr.
23andMe, AFFYMETRIX, ATOSSA GENETICS, NODALITY, deCode /Amgen, CELERA, MYRIAD) - By Geography (US, UK, EU) - By Segment (Targeted therapeutics, Companion Diagnostics
, Esoteric tests, Esoteric lab services) - By Sub-market (Companion diagnostics
& therapeutic, nutrition & wellness, medical technology, pharmacogenomics, consumer genomics)
Although drug companies rely on external partners for companion diagnostics
development, companies still dedicate internal staff to work with new CDx products, finds Cutting Edge Information
This report tackles the growing market interest in pharmacogenomics, companion diagnostics
and the associated market environment.